ReviewJournal of cellular physiology2016
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.
Review in Journal of cellular physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Exploration of the role of immune cells and cell therapy in hepatocellular carcinoma.Frontiers in immunology · 2025Review
- IL-7 armed binary CAR T cell strategy to augment potency against solid tumors.Frontiers in immunology · 2025Article
- Targeting senescent cells with NKG2D-CAR T cells.Cell death discovery · 2024Article
- Who wins the combat, CAR or TCR?Leukemia · 2023Review
- Article
- Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.Pharmacology & therapeutics · 2022Review
- IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma.Molecular therapy oncolytics · 2022Article
- Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.International journal of molecular sciences · 2021Review
- Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells.Molecular cancer therapeutics · 2021Article
- Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer.Molecular therapy oncolytics · 2021Article
- Article
- Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.Oncoimmunology · 2021Article
- A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells.Molecular therapy. Methods & clinical development · 2020Article
- The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Cellular immunology · 2019Review
- Targeting PVR (CD155) and its receptors in anti-tumor therapy.Cellular & molecular immunology · 2019Review
- Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Cytotherapy · 2018Article
- Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.Best practice & research. Clinical haematology · 2018Review
- T-bet promotes potent antitumor activity of CD4Cancer gene therapy · 2018Article
- Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.Cancer immunology, immunotherapy : CII · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chimeric antigen receptor (CAR) T cells have been developed to treat tumors and have shown great success against B cell malignancies. Exploiting modular designs and swappable domains, CARs can target an array of cell surface antigens and, upon receptor-ligand interactions, direct signaling cascades, thereby driving T cell effector functions. CARs have been designed using receptors, ligands, or scFv binding domains. Different regions of a CAR have each been found to play a role in determining the overall efficacy of CAR T cells. Therefore, this review provides an overview of CAR construction and common designs. Each CAR region is discussed in the context of its importance to a CAR's function. Additionally, the review explores how various engineering strategies have been applied to CAR T cells in order to regulate CAR T cell function and activity. J. Cell. Physiol. 231: 2590-2598, 2016. © 2016 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.